摘要
目的·评价阿比特龙(AA)联合泼尼松治疗转移性去势抵抗性前列腺癌(mCRPC)患者的疗效,并分析预后因素。方法·回顾性分析2012年9月—2016年12月上海交通大学医学院附属仁济医院诊治的112例mCRPC患者的临床资料,其中42例先前接受过化疗,70例先前未接受过化疗。观察终点为前列腺特异性抗原无进展生存期(PSA PFS)、影像学无进展生存期(r PFS)以及总生存期(OS)。采用Cox单因素和多因素分析对患者PSA PFS、rPFS以及OS相关的预后因素进行分析。结果·中位随访时间20.2个月,59例患者死亡。中位PSA PFS 8.9(7.8~10.0)个月,中位rPFS 9.7(9.0~10.4)个月,中位OS 22.2(20.3~24.1)个月。多因素分析中,先前是否接受化疗、粒淋比(≥3 vs<3)、血清乳酸脱氢酶水平(≥196 U/L vs<196 U/L)、先前内分泌治疗有效时间(<12个月vs≥12个月)、ECOG评分(≤1 vs 2)与mCRPC患者接受AA联合泼尼松治疗的PSA PFS与rPFS显著相关,先前是否接受化疗、ECOG PS(≤1 vs 2)与OS显著相关。结论·AA联合泼尼松治疗中国mCRPC患者取得较好疗效,先前是否接受化疗、ECOG PS(≤1 vs 2)与接受AA治疗的mCRPC患者OS显著相关。
Objective · To assess the efficacy of abiraterone acetate （AA） plus prednisone treating metastatic castration-resistant prostate cancer （mCRPC） patients and analyze the prognostic factors for this treatment. Methods · The medical history of 112 patients with mCRPC treated in Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, including 70 patients in the chemotherapy-naive setting and 42 in the post-chemotherapy setting, were retrospectively reviewed. Coprimary end points were prostate specific antigen progression-free survival （PSA PFS）, radiographic PFS （rPFS） and overall survival （OS）. Univariable and multivariable Cox analyses were performed to determine prognostic factors that were associated with PSA PFS, rPFS and OS. Results · At a median follow-up of 20.2 months, 59 （52.7%） patients had died. The median PSA PFS, rPFS and OS were 8.9 （7.8 ～ 10.0） months, 9.7 （9.0 ～ 10.4） months, and 22.2 （20.3 ～ 24.1） months, respectively. In multivariate analysis, previous chemotherapy, neutrophil lymphocyte ratio （ ≥ 3 vs〈3）, serum lactate dehydrogenase level （ ≥ 196 U/L vs〈196 U/L） and ECOG PS （ ≤？1 vs 2） were independent predictors for PSA PFS and rPFS, and previous chemotherapy, ECOG PS （ ≤？1 vs 2） remained significant predictors for OS. Conclusion · These results further support the favourable profile of AA plus prednisone in patients with mCRPC in China. Previous chemotherapy, ECOG PS （ ≤？1 vs 2） remained significant predictors for OS.
出处
《上海交通大学学报（医学版）》
CSCD
北大核心
2017年第11期1482-1488,共7页
Journal of Shanghai Jiao tong University:Medical Science
基金
国家自然科学基金(81572536
81672850)
上海市浦东新区卫生系统重点学科群建设(PWZxq2014-05)
上海市教育委员会高峰高原学科建设计划(20152215)~~
关键词
阿比特龙
未经化疗
转移性去势抵抗性前列腺癌
疗效
预后因素
abiraterone acetate
chemotherapy naive
metastatic castration-resistant prostate cancer
efficacy
prognostic factor
